Key Trends Shaping the Future of Cell and Gene Therapy 

Cell and gene therapies are moving beyond early commercialization with the focus shifting to how these treatments are manufactured and delivered. As programs scale, reducing vein-to-vein time and shifting production closer to the point of care are becoming central to how these therapies are delivered, because both directly affect patient access and treatment timelines. 

In a recent article published by Labiotech, Project Farma experts, Joe O’Brien, VP Digital Transformation & Automation, and George Skillin, VP Strategy Services, discuss how decentralized manufacturing models and automation are being used to streamline production, reduce variability, and support more consistent delivery of therapies. Their commentary reflects the growing need for facilities, equipment, and digital systems that can support faster turnaround times while maintaining quality and control. 

Click here to read, ‘The future of cell & gene therapy: Key trends to watch’.